Cervical Cancer Survival Influenced by Presence of Diabetes Mellitus
the Cancer Therapy Advisor take:
Diabetes mellitus (DM) was determined to be an independent unfavorable prognostic factor in Asian patients with early cervical cancer (CC), according to an article published online in the journal The Oncologist.
In this study, 2,946 patients diagnosed with primary stage 2-2A CC and received curative treatments between 2004 and 2008 were identified from the nationwide Taiwan Cancer Registry database. In total, 284 (9.6%) patients had DM.
Results showed patients with DM had significantly lower 5-year cervical cancer-specific survival (CSS) and overall survival (OS) rates compared to patients without DM (CSS: 85.4% vs. 91.5%; OS: 73.9% vs. 87.9%, respectively).
The investigators found that DM remained an independent unfavorable prognostic factor for CSS (aHR, 1.46) and OS (aHR, 1.55), after adjusting for clinicopathologic variables and comorbidities.
The study’s findings indicated that the risk of cancer recurrence and death in patients with early stage CC may be increased by DM, even after receiving curative treatments.
Diabetes mellitus determined to be an independent unfavorable prognostic factor in Asian patients with early cervical cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Ginkgo Biloba and Cancer
- Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC
- Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC
- Curative-intent Surgery for Cancer Increases Risk of New Persistent Opioid-use
- HIV-associated Head and Neck Cancers Have Unique Molecular Characteristics
- Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC
- Cost, Insurance Status May Affect Patient Adherence to TKI Therapy for CML
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured